Silexion Therapeutics (SLXN) Institutional Ownership $0.32 -0.01 (-3.03%) (As of 11/21/2024 ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsOwnershipSEC FilingsTrends Institutional Ownership Changes (13F Filings) for Silexion Therapeutics (NASDAQ:SLXN)CurrentInstitutional OwnershipPercentage10.95%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$536.15KNumber ofInstitutional Sellers(last 12 months)0 Get SLXN Insider Trade Alerts Want to know when executives and insiders are buying or selling Silexion Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Silexion Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/9/2024 Wildcat Capital Management LLC1,020,852$536K0.3%N/A7.381% (Data available from 1/1/2016 forward) SLXN Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of SLXN shares? During the previous two years, the following institutional investors and hedge funds held shares of Silexion Therapeutics shares: Wildcat Capital Management LLC ($536K).Learn more on SLXN's institutional investors. What percentage of Silexion Therapeutics stock is owned by institutional investors? 10.95% of Silexion Therapeutics stock is owned by institutional investors. Learn more on SLXN's institutional investor holdings. Which institutional investors have been buying Silexion Therapeutics stock? The following institutional investors have purchased Silexion Therapeutics stock in the last 24 months: Wildcat Capital Management LLC ($1.02M). How much institutional buying is happening at Silexion Therapeutics? Institutional investors have bought a total of 1,020,852 shares in the last 24 months. This purchase volume represents approximately $536.15K in transactions. Related Companies Inhibikase Therapeutics Major Shareholders IN8bio Major Shareholders AIM ImmunoTech Major Shareholders PharmaCyte Biotech Major Shareholders NKGen Biotech Major Shareholders Turnstone Biologics Major Shareholders Senti Biosciences Major Shareholders Evaxion Biotech A/S Major Shareholders Coeptis Therapeutics Major Shareholders Brainstorm Cell Therapeutics Major Shareholders This page (NASDAQ:SLXN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
